Clearsign Technologies Corp Files For Mixed Shelf Of Up To $50M

-Reuters

-Reuters

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Calquence Approved in Japan for Adults with Treatment Naïve Chronic Lymphocytic Leukaemia

AstraZeneca's Calquence (acalabrutinib), a selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). Calquence was previously approved in Japan for the treatment of adults with relapsed or refractory CLL.

AZN